Method for determining percent platelet aggregation
View Patent ↗A method for obtaining a percent aggregation or inhibition of platelets resulting from anti-platelet using a single blood sample is achieved. An assay device is provided. The assay device has multiple channels, each coupled to a common introduction port. A first platelet activator is sensitive to activation pathway targeted by the anti-platelet drug. A second platelet activator is insensitive to the activation pathway targeted by the anti-platelet drug. An anti-coagulated sample is introduced simultaneously to the first and second channels. A level of platelet aggregation is simultaneously made in both channels.
1. A method for obtaining a percent activation of aggregation or inhibition of aggregation of platelets in an anti-coagulated blood sample from an individual treated with an anti-platelet drug, comprising:
(a) providing an assay device having a first channel (Test Channel) and a second channel (Control Channel);
(b) introducing a first platelet activator to the first channel (Test Channel) of the assay device, the platelet activator being sensitive to an activation pathway targeted by the anti-platelet drug;
(c) introducing a second platelet activator to the second channel (Control Channel) of the assay device, the second platelet activator being insensitive to the activation pathway targeted by the anti-platelet drug;
(d) introducing the anti-coagulated blood sample to the assay device;
(e) simultaneously measuring a level of platelet aggregation in both channels; and
(f) determining a percent platelet aggregation (PA) or inhibition (PI) as follows:
% PA=(Test Channel/Control Channel)*100%
% PI=(1−(Test Channel/Control Channel))*100%=100%−% PA.
2. The method of claim 1 , wherein the first platelet activator is selected from the group consisting of arachidonic acid, ADP, collagen, thromboxane A2 and epinephrine.
3. The method of claim 1 , wherein the second platelet activator is selected from the group consisting of thrombin and iso-thrombin receptor-activating peptide (iso-TRAP).
4. The method of claim 1 , wherein the anti-coagulated sample is selected from the group consisting of undiluted whole blood, plasma and diluted whole blood.
5. The method of any of the preceding claims, wherein the anti-platelet drug is clopidogrel.